Soleno Therapeutics (SLNO) Cash & Equivalents: 2013-2018
Historic Cash & Equivalents for Soleno Therapeutics (SLNO) over the last 6 years, with Dec 2018 value amounting to $23.1 million.
- Soleno Therapeutics' Cash & Equivalents rose 9.63% to $11.2 million in Q3 2019 from the same period last year, while for Sep 2019 it was $11.2 million, marking a year-over-year increase of 9.63%. This contributed to the annual value of $23.1 million for FY2018, which is 35.08% up from last year.
- Soleno Therapeutics' Cash & Equivalents amounted to $23.1 million in FY2018, which was up 35.08% from $17.1 million recorded in FY2017.
- In the past 5 years, Soleno Therapeutics' Cash & Equivalents registered a high of $23.1 million during FY2018, and its lowest value of $2.7 million during FY2016.
- Its 3-year average for Cash & Equivalents is $14.3 million, with a median of $17.1 million in 2017.
- In the last 5 years, Soleno Therapeutics' Cash & Equivalents crashed by 50.39% in 2016 and then spiked by 527.29% in 2017.
- Yearly analysis of 5 years shows Soleno Therapeutics' Cash & Equivalents stood at $8.0 million in 2014, then tumbled by 30.94% to $5.5 million in 2015, then crashed by 50.39% to $2.7 million in 2016, then soared by 527.29% to $17.1 million in 2017, then spiked by 35.08% to $23.1 million in 2018.